A Phase 1 Study of Multiple Oral Doses of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus
Status:
Not yet recruiting
Trial end date:
2022-05-03
Target enrollment:
Participant gender:
Summary
This is a Phase 1, randomized, placebo-controlled, double-blind (investigator- and
participant-blinded), sponsor-open study of PF-07081532. Study participants will receive the
investigational product or placebo every day for 42 days.
The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics (PK) of
multiple oral doses of PF-07081532 in participants with inadequately controlled type 2
diabetes mellitus, on metformin and optionally in non-diabetic participants with obesity.